Citations

Clear

4610 citation(s) found for "Lu, Brian".

O21 Long-term efficacy and safety of filgotinib 200 mg in ulcerative colitis: 5-year interim data from SELECTIONLTE
Arnott, Ian , Feagan, Brian G. , Schreiber, S, Kim, Hyo Jong , Faes, Margaux , Mangili, Alexandra, Peyrin-Biroulet, Laurent, Matsuoka, Katsuyoshi , Rogler, Gerhard , Laharie, David , Vermeire, Séverine , Danese, Silvio , Loftus, Edward V. , Beales, Ian , Schreiber, Stefan , Rudolph, Christine , Peyrin‐Biroulet, Laurent

Mayo Clinic

Oral Presentations | June 23, 2025 | Volume: No volume available | Issue: No issue available | Pages: A15-A15

10.1136/gutjnl-2025-bsg.21 Get It

P68 Mirikizumab versus placebo: histologic inflammation in 5 intestinal segments in randomized controlled phase 3 trial for crohn’s disease participants
Feagan, Brian G., Hisamatsu, Tadakazu , D’Haens, Geert , Pai, Rish K. , Lin, Zhantao, Protić, Marijana , Hon, Emily, Escobar, Rodrigo , Reinisch, Walter , Dhesi, Endip , Jairath, Vipul , Magro, Fernando , Hertogh, Gert D. , Harpaz, Noam , Morris, Nathan , Owen, Charles, Reinisch, Walter

Mayo Clinic

Posters | June 23, 2025 | Volume: No volume available | Issue: No issue available | Pages: A129.2-A130

10.1136/gutjnl-2025-bsg.204 Get It

ACR–ARS Practice Parameter for Image-Guided Radiation Therapy (IGRT)
Garsa, Adam , Buckey, C, Freedman, Laura , Gros, Sebastien , Hallemeier, Christopher L. , Lo, Simon S. , Milano, Michael T. , Saeed, Hina , Ye, Jason C. , Schechter, Naomi R., Buckey, Courtney R, Davis, Brian J. , Hallemeier, Christopher Leigh , Small, William

Mayo Clinic

American Journal of Clinical Oncology | June 20, 2025 | Volume: 48 | Issue: 11 | Pages: 529-539

10.1097/coc.0000000000001220 | PMID 40539501 Get It

Objectives: This practice parameter was revised collaboratively by the American College of Radiology (ACR), and American Radium Society (ARS). Image-guided radiation therapy (IGRT) uses various imaging modalities to maximize the accuracy and precision of radiation treatment delivery. Methods: This practice parameter was developed according to the process described under the heading The Process for Developing ACR Practice Parameters and Technical Standards on the ACR website (https://www.acr.org/Clinical-Resources/Practice-Parameters-and-Technical-Standards) by the Committee on Practice Parameters–Radiation Oncology of the ACR Commission on Radiation Oncology in collaboration with the ARS. Results: This practice parameter for IGRT addresses qualifications and responsibilities of personnel, clinical IGRT implementation, documentation, quality control and improvement, safety, and patient education. Since the publication of the ACR–ASTRO Practice Parameter in 2019, there is now more clarity as to what criteria and parameters need to be documented in the medical record, a better appreciation of the large amount of imaging data, how to interpret such data, as well as the complex interactions of multiple systems in the implementation of IGRT. Conclusions: This practice parameter assists practitioners in the clinical use of IGRT. IGRT should complement and be used in combination with other quality assurance processes. IGRT is a rapidly evolving field, and practitioners should have a thorough understanding of its strengths and potential limitations.
Surgical Treatment and Complications of Lateral Extra‐articular Procedures in the Anterior Cruciate Ligament–Reconstructed Knee: Part II of an International Consensus Statement
Sonnery‐Cottet, Bertrand , Carrozzo, Alessandro , Saithna, Adnan , Vieira, Thaïs Dutra , Musahl, Volker , Helito, Camilo Partezani , Panel, The International Experts, Bedi, Asheesh, Bryant, Dianne, Cavaignac, Etienne, Chahla, Jorge, Claes, Steven, Cordasco, Frank, Daggett, Matt, Devitt, Brian, Feller, Julian, Fink, Christian, Frank, Rachel, Geeslin, Andrew, Grassi, Alberto, Green, Daniel, Guenther, Daniel, Heard, Mark, Herbst, Elmar, Hopper, Graeme, Inderhaug, Eivind, Irrgang, James, Kaeding, Christopher, Kittl, Christopher, Kocher, Mininder, Koga, Hideyuki, Krych, Aaron J., LaPrade, Robert, Levy, Bruce, Litchfield, Robert Bruce, Lording, Tim, Lowe, Walter, MacDonald, Peter, Marx, Robert, Moatshe, Gilbert, Neri, Thomas, Ouanezar, Herve, Padua, Vitor Barion de Castro, Parker, David, Pioger, Charles, Servien, Elvire, Sherman, Seth, Smith, Patrick, Spalding, Tim, Tapasvi, Sachin, Verdonk, Peter, Williams, Andy, Xerogeanes, John, Young, Simon W., Monaco, Edoardo , Getgood, Alan , Panel, The International Experts, Bedi, Asheesh, Bryant, Dianne, Cavaignac, Etienne, Chahla, Jorge, Claes, Steven, Cordasco, Frank, Daggett, Matt, Devitt, Brian, Feller, Julian, Fink, Christian, Frank, Rachel, Geeslin, Andrew, Grassi, Alberto, Green, Daniel, Guenther, Daniel, Heard, Mark, Herbst, Elmar, Hopper, Graeme, Inderhaug, Eivind, Irrgang, James, Kaeding, Christopher, Kittl, Christopher, Kocher, Mininder, Koga, Hideyuki, Krych, Aaron J., LaPrade, Robert, Levy, Bruce, Litchfield, Robert Bruce, Lording, Tim, Lowe, Walter, MacDonald, Peter, Marx, Robert, Moatshe, Gilbert, Neri, Thomas, Ouanezar, Herve, Padua, Vitor Barion de Castro, Parker, David, Pioger, Charles , Servien, Elvire, Sherman, Seth, Smith, Patrick, Spalding, Tim, Tapasvi, Sachin, Verdonk, Peter, Williams, Andy, Xerogeanes, John, Young, Simon W.

Mayo Clinic

Arthroscopy | June 20, 2025 | Volume: 41 | Issue: 9 | Pages: 3313-3321

10.1016/j.arthro.2025.06.013 | PMID 40544924 Get It

Purpose To establish international expert consensus on surgical techniques, complications, and rehabilitation protocols for lateral extra‐articular procedures (LEAPs) performed adjunctively with anterior cruciate ligament reconstruction. Methods Fifty‐five knee surgeons from 17 countries on 5 continents completed a 3‐round modified Delphi process. In the final round, 16 statements on LEAP techniques and complications were scored on a 5‐point Likert scale; ≥75% “agree/strongly agree” constituted consensus. When appropriate, strength of recommendation was graded. Statements lacking support were revised until consensus or abandonment. Results Six statements achieved unanimous consensus (100%), 2 had strong consensus (90%‐99.9%), and 3 reached consensus (75%‐89.9%); 4 were removed. Key technical recommendations were as follows: (1) in iliotibial band procedures, the graft strip should pass beneath the lateral collateral ligament; (2) an anatomic technique is mandatory for anterolateral ligament reconstruction; and (3) no single LEAP is clinically superior to another. Unanimous agreement indicated that modern LEAPs do not increase lateral compartment osteoarthritis risk, carry a low complication rate, and do not necessitate changes to rehabilitation or return‐to‐play timelines. Conclusions Consensus defined core surgical principles and confirmed the safety of adding LEAPs to anterior cruciate ligament reconstruction. When an iliotibial band graft is used, it should be routed deep to the lateral collateral ligament and fixed between 0° and 60° of knee flexion under low tension. For anterolateral ligament reconstruction, femoral fixation should be in full extension at a posterior‐proximal point relative to the lateral epicondyle. Although no single LEAP proved superiority, adherence to these principles permits safe, effective surgery without altering standard rehabilitation or return‐to‐sport protocols and without increasing osteoarthritis risk. Level of Evidence Level V, expert opinion.
Indications for Lateral Extra‐articular Procedures in the Anterior Cruciate Ligament–Reconstructed Knee: Part I of an International Consensus Statement
Sonnery‐Cottet, Bertrand , Carrozzo, Alessandro , Saithna, Adnan , Vieira, Thaïs Dutra , Musahl, Volker , Helito, Camilo Partezani , Panel, The International Experts, Bedi, Asheesh, Bryant, Dianne, Cavaignac, Etienne, Chahla, Jorge, Claes, Steven, Cordasco, Frank, Daggett, Matt, Devitt, Brian, Feller, Julian, Fink, Christian, Frank, Rachel, Geeslin, Andrew, Grassi, Alberto, Green, Daniel, Guenther, Daniel, Heard, Mark, Herbst, Elmar, Hopper, Graeme, Inderhaug, Eivind, Irrgang, James, Kaeding, Christopher, Kittl, Christopher, Kocher, Mininder, Koga, Hideyuki, Krych, Aaron J., LaPrade, Robert, Levy, Bruce, Litchfield, Robert Bruce, Lording, Tim, Lowe, Walter, MacDonald, Peter, Marx, Robert, Moatshe, Gilbert, Neri, Thomas, Ouanezar, Herve, Padua, Vitor Barion de Castro, Parker, David, Pioger, Charles, Servien, Elvire, Sherman, Seth, Smith, Patrick, Spalding, Tim, Tapasvi, Sachin, Verdonk, Peter, Williams, Andy, Xerogeanes, John, Young, Simon W., Sherman, Seth L. , Monaco, Edoardo , Getgood, Alan , Panel, The International Experts, Bedi, Asheesh, Bryant, Dianne, Cavaignac, Etienne, Chahla, Jorge, Claes, Steven, Cordasco, Frank, Daggett, Matt, Devitt, Brian, Feller, Julian, Fink, Christian, Frank, Rachel, Geeslin, Andrew, Grassi, Alberto, Green, Daniel, Guenther, Daniel, Heard, Mark, Herbst, Elmar, Hopper, Graeme, Inderhaug, Eivind, Irrgang, James, Kaeding, Christopher, Kittl, Christopher, Kocher, Mininder, Koga, Hideyuki, Krych, Aaron J., LaPrade, Robert, Levy, Bruce, Litchfield, Robert Bruce, Lording, Tim, Lowe, Walter, MacDonald, Peter, Marx, Robert, Moatshe, Gilbert, Neri, Thomas, Ouanezar, Herve, Padua, Vitor Barion de Castro, Parker, David, Pioger, Charles , Servien, Elvire, Sherman, Seth, Smith, Patrick, Spalding, Tim, Tapasvi, Sachin, Verdonk, Peter, Williams, Andy, Xerogeanes, John, Young, Simon W.

Mayo Clinic

Arthroscopy | June 20, 2025 | Volume: 41 | Issue: 9 | Pages: 3303-3312

10.1016/j.arthro.2025.06.012 | PMID 40544926 Get It

Purpose To define expert consensus on whether and how lateral extra‐articular procedures (LEAPs) should accompany anterior cruciate ligament (ACL) reconstruction to optimize outcomes in ACL‐deficient knees. Methods Fifty‐five knee surgeons from 17 countries on 5 continents completed a 3‐round modified Delphi process. Twenty‐one statements on patient selection for combined ACL reconstruction (ACLR) + LEAPs were graded on 5‐point Likert scales; ≥75% “agree/strongly agree” signified consensus. Strength of recommendation was ranked, and statements failing the threshold were revised or discarded after discussion. Results One statement achieved unanimous agreement (100%): it is strongly recommended to add a LEAP for active patients ≤25 years receiving hamstring‐autograft ACLR to reduce graft failure. Strong consensus (≥90%) supported LEAPs in primary ACLR when grade 3 pivot shift (97.9%), knee hyperextension (97.9%), skeletally immature status (79.5%), revision ACLR (91.5%), return to pivoting sports (93.2%), active patients ≤25 years using nonhamstring grafts (90.7%), grade 3 Lachman test (90%), and when multiple relative risk factors coexist (statement 36, 97.1%). Consensus (75%‐89.9%) favored LEAPs for chronic symptomatic ACL deficiency (86.1%), posterior tibial slope >12° (85.7%), and a history of contralateral ACL injury (88.9%). Eight statements did not reach consensus regarding small‐diameter autografts, female athletes, imaging signs of anterolateral injury (e.g., Segond fracture, lateral femoral‐notch sign), and concomitant meniscal procedures. One statement on LEAPs with primary ACL repair was withdrawn because the project focused on reconstruction. Conclusions International experts strongly recommend adding a LEAP in young active patients undergoing hamstring‐autograft ACLR and in cases of high‐grade rotational or anterior laxity, knee hyperextension, revision surgery, or returning to pivoting sports. Unresolved issues include small graft size, female athletes, imaging findings of rotational instability, and concurrent meniscal procedures, highlighting priorities for future research. Level of Evidence Level V, expert opinion.
Measurement of Value in Uncomplicated Total Knee Arthroplasty
Kleinsmith, Rebekah M. , Puckett, Haley D. , Banfield, Nicholas , Bothun, Cole E. , Doxey, Stephen A. , Horst, Patrick K. , Bingham, Joshua S. , Cunningham, Brian P. , Banfield, Nicholas F , Bingham, Joshua S

Mayo Clinic

Journal of Bone and Joint Surgery | June 19, 2025 | Volume: 107 | Issue: 15 | Pages: 1680-1689

10.2106/jbjs.24.01485 | PMID 40536933 Get It

Background: Patient-level value analysis (PLVA) has been applied to several orthopaedic procedures but has not yet been utilized to assess the value of total knee arthroplasty (TKA). The purpose of this study was to evaluate the 1-year episode of care for TKA with use of PLVA to identify characteristics that influence value at both the patient and surgeon level. Methods: The institutional patient-reported outcome (PRO) database was queried for all patients who underwent TKA from 2020 to 2022. Patients were excluded on the basis of an index revision procedure, a pathology other than primary osteoarthritis, unicompartmental knee arthroplasty, robotic-assisted TKA, incomplete baseline or 1-year PROs, concomitant procedures (i.e., bilateral TKA or hardware removal), complications requiring readmission or reoperation, TKA without patellar resurfacing, the use of constrained implants, incomplete cost information, or other hip or knee arthroplasty procedure during the 1-year episode of care. PROs of interest included preoperative and 1-year postoperative Knee injury and Osteoarthritis Outcome Score-Joint Replacement (KOOS-JR) scores. Episode-of-care costs were calculated using time-driven activity-based costing. The 1-year value quotient (V KOOS ) was calculated for each patient as the ratio of the 1-year change in KOOS-JR score to the total episode-of-care cost. Results: A total of 684 patients (62% female; mean age, 68 ± 8 years) met the inclusion criteria. The mean KOOS-JR score significantly increased from baseline (53 ± 11) to 1 year (79 ± 14; p < 0.001), with a mean improvement of 26 ± 16. The mean total episode-of-care cost was $9,563 ± $2,370. There was no significant correlation between episode-of-care costs and the change in KOOS-JR score (r = 0.02; p = 0.581). Surgery performed at an ambulatory surgery center (p < 0.001) and as an outpatient procedure (p = 0.036) were predictive of lower costs. Patient-specific instrumentation (p < 0.001) and a tibial stem extension (p < 0.001) were predictive of higher costs. Older age (p = 0.023) and male sex (p = 0.007) were predictive of less improvement in KOOS-JR scores from baseline to 1 year. Conclusions: Our study identified patient and surgical characteristics that drive costs and PROs in TKA. PLVA can be used to identify “bright spots” in orthopaedic procedures to optimize care delivery. Level of Evidence: Prognostic Level IV . See Instructions for Authors for a complete description of levels of evidence.
Impact of SGLT2i on Cardiovascular Outcomes Following Acute Myocardial Infarction With Heart Failure With Preserved Ejection Fraction: Propensity-matched Registry Study
Calcagno, Tess , Issa, Rochell , Canova, Tyler , Issa, Ryan, Menon, Venu , Griffin, Brian P. , Kwon, Deborah , Wang, Tom Kai Ming , Wang, Tom Kai Ming , Kaelber, David C. , Tang, Weihong

Mayo Clinic

Angiology | June 19, 2025 | Volume: 77 | Issue: 7 | Pages: 875-882

10.1177/00033197251345853 | PMID 40534435 Get It

Sodium-glucose co-transporter-2 inhibitors (SGLT2i) have demonstrated benefits in heart failure with preserved ejection fraction (HFpEF), but their impact following acute myocardial infarction (AMI) is less well understood. Using the TriNetX Research Network (TriNetX) multi-center registry (2014–2022), we identified patients with heart failure with preserved ejection fraction (HFpEF)—defined as left ventricular ejection fraction (LVEF) >50% and New York Heart Association (NYHA) class II–IV—not previously treated with sodium-glucose co-transporter 2 inhibitors (SGLT2i) who experienced an acute myocardial infarction (AMI). Patients who initiated SGLT2i within 1-year post-AMI were compared with those who did not. Propensity score matching was used to balance cohorts ( n = 20,423 each; mean age 68.3 ± 11.0 years; 54.5% female) for demographics, comorbidities, and treatment variables. The primary outcome was a composite of major adverse cardiovascular events (MACE), including all-cause mortality, recurrent AMI, acute heart failure, and stroke. Secondary outcomes included cardiac arrest and major bleeding. SGLT2i use was associated with lower rates of MACE (3.7% vs 6.1%; P = .0005), all-cause mortality (0.9% vs 5.6%; P < .0001), and other adverse events at both 30 days and 1 year. In this large, propensity-matched cohort, SGLT2i use post-AMI in HFpEF patients was associated with favorable cardiovascular outcomes. Further studies are needed to confirm these associations.
Transcranial Electrical Stimulation in Treatment of Depression
Ren, Caili , Wang, Zhen , Kung, Simon , Boyapati, Renu Bhargavi, Islam, Karimul , Li, John Wing , Shelton, K. Maureen, Waniger, Anne , Rydberg, Ann , Pascual–Leone, A., Pagali, Sandeep R. , Li, John W, Rydberg, Ann M, Boyapati, Renu Bhargavi, Islam, Karimul, Hassett, Leslie C. , Croarkin, Paul E. , Lundstrom, Brian N. , Lapid, Maria I.

Mayo Clinic

JAMA Network Open | June 18, 2025 | Volume: 8 | Issue: 6 | Pages: e2516459

10.1001/jamanetworkopen.2025.16459 | PMID 40531534 Get It

Importance The role and safety of transcranial electrical stimulation (tES) for treating depressive disorders remain under evaluation. Objective To evaluate tES treatment in patients with major depressive disorder (MDD) and comorbid depressive conditions. Data Sources A search of MEDLINE, Embase, Cochrane, APA PsycINFO, and Scopus databases was conducted from inception to September 17, 2024. Study Selection Randomized clinical trials (RCTs) of adults with MDD, depression with psychiatric comorbidities (DPC), or depression with medical comorbidities (DMC), treated with transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), or transcranial random noise stimulation (tRNS), compared with sham or other treatments were included. Data Extraction and Synthesis Independent reviewers extracted data in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines, with random-effects meta-analysis used for pooling. Main Outcomes and Measures Primary outcomes were depression severity, response and remission rates, and adverse events. Standardized mean differences (SMDs) were reported for continuous outcomes, and odds ratios (ORs) were reported for categorical outcomes. Quality of evidence (QOE) was assessed using the Grading of Recommendations Assessment, Development, and Evaluation criteria. Results The meta-analysis included 5522 participants from 114 study groups from 88 RCTs (3198 female [58.9%]; mean [range] age, 43.1 [19.4-76.9] years). Most studies (104 study groups from 79 RCTs [91.2%]) evaluated tDCS, while 7 study groups from 6 RCTs (6.1%) evaluated tACS, and 3 study groups from 3 RCTs (2.7%) evaluated tRNS. tES was associated with reduced depressive symptoms (SMD = −0.59; 95% CI, −0.83 to −0.35; low QOE) and improvement in DMC (SMD = −1.05; 95% CI, −1.67 to −0.43; low QOE) and DPC (SMD = −0.78; 95% CI, −1.27 to −0.29; low QOE) compared with MDD (SMD = −0.22; 95% CI, −0.44 to 0.01; low QOE). tDCS was associated with reduced depression in DMC (SMD = −1.05; 95% CI, −1.70 to −0.40; very low QOE) and DPC (SMD = −0.88; 95% CI, −1.40 to −0.36; low QOE) but not MDD. tACS was associated with improved MDD symptoms (SMD = −0.58; 95% CI, −0.96 to −0.20; high QOE) and response rates (OR, 2.07; 95% CI, 1.34 to 3.19; high QOE). Combined tDCS and medication was associated with reduced symptoms (SMD = −0.51; 95% CI, −0.90 to −0.13; moderate QOE) and increased response (OR, 2.25; 95% CI, 1.08 to 4.65; high QOE) in MDD. tDCS combined with psychotherapy was not associated with improvement. Subgroup analysis showed that anodal left dorsolateral prefrontal cortex DCS was associated with improved outcomes. Mild to moderate adverse events were more frequent in tES groups. Conclusions and Relevance In this systematic review and meta-analysis, tDCS was associated with improvement in depression among patients with DMC and DPC (with smaller benefits in MDD), tACS was associated with improved MDD outcomes (while tRNS had insufficient evidence) in smaller samples, and combined tDCS and medication was associated with improvement in depression. These findings suggest that tES is well-tolerated overall, with only mild to moderate adverse events, and that future research should optimize stimulation parameters and individualize tES interventions.
Treatment outcomes of successful M1 versus M2 thrombectomy for low-ASPECTS stroke patients
Chen, Huanwen , Colasurdo, Marco , Maier, Ilko , Jabbour, Pascal , Kim, Joon-Tae , Wolfe, Stacey Q , Rai, Ansaar , Starke, Robert M. , Psychogios, Marios‐Nikos, Yoshimura, Shinichi , Alaraj, Ali , Ezzeldin, Mohamad , Tanweer, Omar , Polifka, Adam , Siddiqui, Fazeel , Crosa, Roberto , Levitt, Michael R, Brinjikji, Waleed , Moss, Mark, Dağlıoğlu, Ergün , Williamson, Richard , Chowdhry, Shakeel , Altschul, David , Spiotta, Alejandro M , Kan, Peter, Jabbour, Pascal , Wolfe, Stacey Quintero , Yoshimura, Shinichi , Cuellar-Saenz, Hugo H , Alaraj, Ali , Ezzeldin, Mohamad , Fragata, Isabel , Grandhi, Ramesh , Matouk, Charles , Altschul, David J , Crosa, Roberto , Colasurdo, Marco , Matsukawa, Hidetoshi , Cunningham, Conor M. , Shaban, Amir , Goyal, Nitin , Cuellar, Hugo , Howard, Brian M , Alawieh, Ali , Romano, Daniele Giuseppe , Mascitelli, Justin R , Fragata, Isabel , Osbun, Joshua W , Grandhi, Ramesh , Matouk, Charles , Park, Min S. , Navía, Pedro , Chen, Huanwen

Mayo Clinic

Interventional Neuroradiology | June 18, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15910199251343283 | PMID 40530425 Get It

Background The effectiveness of endovascular thrombectomy (EVT) for low Alberta Stroke Program Early CT score (ASPECTS) stroke patients with occlusion of the second segment of the middle cerebral artery (M2) is unclear. Methods This was a multicenter retrospective study. Patients with M1 or M2 occlusions and low ASPECTS (<6) who underwent successful EVT (modified treatment in cerebral ischemia score of 2b or higher) were included. Primary outcome was futile EVT reperfusion (defined as 90-day modified Rankin scale of 5 or 6). Other outcomes of interest include acceptable outcomes (modified Rankin scale of 3 or less) and intracranial hemorrhage (ICH), and all-cause 90-day mortality. Outcomes for M1 patients were compared to M2 patients with multivariable logistic regression models accounting for potential confounders. Results 173 patients with M1 or M2 occlusions and low ASPECTS (<6) who underwent successful EVT were identified. After multivariable adjustments, M2 patients had significantly higher odds of futile reperfusion (OR 5.48 [95%CI 1.91 to 15.7], p = 0.002), lower odds of acceptable outcomes (OR 0.33 [95%CI 0.12 to 0.89], p = 0.028), and higher odds of all-cause mortality (OR 4.90 [95%CI 1.65 to 14.5], p = 0.004). These findings suggest that EVT's efficacy for low-ASPECTS stroke patients may be diminished for patients with M2 occlusions. M2 occlusion was not significantly associated with ICH. Conclusions Among low-ASEPCTS stroke patients who underwent successful EVT, those with M2 occlusions had significantly higher odds of poor outcome compared to those with M1 occlusions.
Defining Clinically Meaningful Subgroups in Patients Undergoing Arthroscopic Rotator Cuff Repair Using Unsupervised Machine Learning
Lu, Yining, Berlinberg, Elyse J. , Alder, Kareme D. , Chervonski, Ethan , Patel, Harsh, Rice, Morgan W. , Yanke, Adam B. , Cole, Brian J. , Verma, Nikhil N. , Hevesi, Mario , Alder, Kareme, Forsythe, Brian , Hevesi, Mario , Patel, Harsh H. , Forsythe, Brian

Mayo Clinic

Orthopaedic Journal of Sports Medicine | June 17, 2025 | Volume: 13 | Issue: 6 | Pages: No page available

10.1177/23259671251335977 | PMID 40535587 Get It

Background: Outcomes after arthroscopic rotator cuff repair (RCR) are frequently measured through clinically significant outcomes (CSOs) such as the minimal clinically important difference, the substantial clinical benefit, and the Patient Acceptable Symptom State. Global achievement of CSOs is challenging to predict. Purpose: To determine if unsupervised machine learning can identify distinct patient subgroups based on CSO achievement after elective arthroscopic RCR. Study Design: Case-control study; Level of evidence, 3. Methods: A prospectively collected database was analyzed to identify patients who underwent elective arthroscopic RCR from 2015 to 2017. Tear dimensions were measured on magnetic resonance imaging utilizing a validated technique. CSO achievements on the American Shoulder and Elbow Surgeons, the Single Assessment Numeric Evaluation, and the Constant-Murley subjective score at 2-year follow-up were calculated. An unsupervised random forest algorithm was utilized to develop and internally validate patient subgroups with significantly different rates of CSO achievement. Patient subgroup membership, along with a total of 30 demographic and clinical variables, as well as preoperative patient-reported outcomes, were incorporated into a stepwise multivariable logistic regression to identify factors predictive of optimal CSO achievement. Results: A total of 346 patients (192 male; mean ± SD age, 57.2 ± 9.1 years; body mass index, 30.1 ± 5.4 kg/m 2 ) were eligible for inclusion and followed for a mean of 3.8 years (range, 2.0-6.2 years) Of these, a total of 333 patients were partitioned by the random forest algorithm into 2 subgroups (stability, 0.16; connectivity: 180.8; Dunn: 0.16; silhouette: 0.05), with 176 patients in the optimal achievement subgroup and 157 patients in the suboptimal achievement subgroup. The 2 subgroups differed significantly (all P ≤ .004) in the likelihood of achievement of all CSOs. Stepwise multivariable logistic regression identified an increase of 1 mm in tear size in the sagittal dimension beyond 1.9 cm to predict a 10% increase in the probability of suboptimal achievement. Additional risk factors for suboptimal CSO achievement included increasing number of tendons involved (odds ratio [OR], 14.07; 95% CI, 4.50-44.02; P < .001), subscapularis involvement (OR, 8.67; 95% CI, 2.45-30.71; P = .01), and increased preoperative CMS score (OR, 1.11; 95% CI, 1.04-1.18; P = .001). Protective factors included performance of a subpectoral biceps tenodesis compared with biceps tenotomy (OR, 0.22; 95% CI, 0.05-0.92; P = .03). Conclusion: Clinically meaningful subgroups were uncovered using an unsupervised machine learning algorithm in patients undergoing arthroscopic RCR. Tear size, number of tendons involved, and subscapularis involvement were significant and additive predictors of suboptimal CSO achievement at 2-year minimum follow-up. Treatment of concurrent biceps pathology with tenodesis conferred 78% increased likelihood of CSO achievement compared with tenotomy.